Brief: Rhythm Pharmaceuticals Says PDUFA Goal Date For Setmelanotide Is March 20, 2026
01/03/2026 17:31
March 1 (Reuters) - Rhythm Pharmaceuticals Inc RYTM.O: RHYTHM PHARMACEUTICALS ANNOUNCES ADDITIONAL POSITIVE DATA FROM PHASE 3 TRANSCEND TRIAL OF SETMELANOTIDE IN PATIENTS WITH ACQUIRED HYPOTHALAMIC OBESITY RHYTHM PHARMACEUTICALS INC - PDUFA GOAL DATE FOR SETMELANOTIDE IS MARCH 20, 2026 RHYTHM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED WITH 16.4% BMI REDUCTION Source text: ID:nGNXcZVpt Further company coverage: RYTM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rhythm Pharmaceuticals
See all newsBrief: Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer
Rhythm's drug shows promise for brain tumor-related weight condition in small study (updated)
Rhythm Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rhythm Pharma's obesity drug shows promise for brain tumor-related weight condition
Rhythm Pharmaceuticals Q2 net loss narrows on US launch demand